PT-141 Palatin

Petter Hedlund

Research output: Contribution to journalArticlepeer-review


Palatin, under license from Competitive Technology, is developing the peptide PT-141, a synthetically modified analog of PT-14, as a nasal spray for the potential treatment of erectile dysfunction (ED) and female sexual dysfunction. In September 2003, Palatin had completed a phase IIb trial in patients with ED and in February 2004, Palatin planned to start phase III trials in early 2005.

Original languageEnglish
Pages (from-to)456-462
Number of pages7
JournalCurrent Opinion in Investigational Drugs
Issue number4
Publication statusPublished - Apr 2004

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology


Dive into the research topics of 'PT-141 Palatin'. Together they form a unique fingerprint.

Cite this